Jazz Pharmaceuticals (JAZZ) Stock Price, News & Analysis

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" JAZZ shares.
View JAZZ analyst ratings or view top-rated stocks.

13 analysts have issued twelve-month price targets for Jazz Pharmaceuticals' shares. Their JAZZ share price targets range from $131.00 to $230.00. On average, they anticipate the company's share price to reach $195.08 in the next twelve months. This suggests a possible upside of 80.0% from the stock's current price.
View analysts price targets for JAZZ or view top-rated stocks among Wall Street analysts.

Jazz Pharmaceuticals' stock was trading at $123.00 at the beginning of 2024. Since then, JAZZ shares have decreased by 11.9% and is now trading at $108.37.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our JAZZ earnings forecast.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) posted its quarterly earnings data on Wednesday, February, 28th. The specialty pharmaceutical company reported $4.40 earnings per share for the quarter, missing analysts' consensus estimates of $4.44 by $0.04. The specialty pharmaceutical company had revenue of $1.01 billion for the quarter, compared to analysts' expectations of $1.01 billion. Jazz Pharmaceuticals had a trailing twelve-month return on equity of 31.27% and a net margin of 10.82%.

ETFs with the largest weight of Jazz Pharmaceuticals (NASDAQ:JAZZ) stock in their portfolio include Cambria Cannabis ETF (TOKE), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), VanEck Pharmaceutical ETF (PPH), Invesco Pharmaceuticals ETF (PJP), iShares U.S. Pharmaceuticals ETF (IHE), First Trust Nasdaq Pharmaceuticals ETF (FTXH) and AdvisorShares Pure Cannabis ETF (YOLO).

Jazz Pharmaceuticals issued an update on its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share (EPS) guidance of 18.150-19.350 for the period, compared to the consensus EPS estimate of 19.940. The company issued revenue guidance of $4.0 billion-$4.2 billion, compared to the consensus revenue estimate of $4.1 billion.

60 employees have rated Jazz Pharmaceuticals Chief Executive Officer Bruce C. Cozadd on Glassdoor.com. Bruce C. Cozadd has an approval rating of 92% among the company's employees. This puts Bruce C. Cozadd in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Jazz Pharmaceuticals investors own include Ligand Pharmaceuticals (LGND), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), NVIDIA (NVDA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV), Bank of America (BAC) and Biogen (biib).

Jazz Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Perpetual Ltd (0.75%), Los Angeles Capital Management LLC (0.32%), Centre Asset Management LLC (0.11%), Hennion & Walsh Asset Management Inc. (0.04%), Alaska Permanent Fund Corp (0.03%) and Signet Financial Management LLC (0.02%). Insiders that own company stock include Anne Oriordan, Bruce C Cozadd, Bruce C Cozadd, Christopher J Tovey, Elmar Schnee, Finbar Larkin, James E Flynn, Jennifer E Cook, Kenneth W O'keefe, Kim Sablich, Mark Douglas Smith, Neena M Patil, Patricia Carr, Patrick G Enright, Peter Gray, Philip L Johnson, Renee D Gala, Rick E Winningham, Robert Iannone and Samantha Pearce.
View institutional ownership trends.

Shares of JAZZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.